Epigenetic modifications affect hepatic lipid metabolism, insulin resistance, mitochondrial function, oxidative stress, and therefore, the assessment of microRNAs has been used for early detection and monitoring of NAFLD progression, and to assess clinical and subclinical CVD [11,12,13]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.